Fulcrum Therapeutics, Inc. (FULC) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Fulcrum Therapeutics reported revenue of $0, down 100.0% from $80.0M the year before. Net income was -$74.9M, or -$1.18 per diluted share. Operating activities generated -$60.1M of cash, leaving -$60.4M of free cash flow. At fiscal year end, Fulcrum Therapeutics held $366.3M in total assets against $17.3M in total liabilities, including $197.5M of cash and equivalents.
Open the full interactive Fulcrum Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Fulcrum Therapeutics Key Stats
| Share Price | $3.68 |
|---|---|
| Market Cap | $280.7M |
| Revenue YoY Growth | -100.0% |
| 52-Week Range | $3.14 – $14.60 |
| Shares Outstanding | 76.3 million (basic, 2026 Q2) |
Fulcrum Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $8.8M | $19.2M | $6.3M | $2.8M | $80.0M | $0 |
| Operating Income | -$71.6M | -$81.1M | -$112.6M | -$110.7M | -$21.9M | -$84.8M |
| Pre-Tax Income | -$70.8M | -$80.8M | -$109.9M | -$97.3M | -$9.7M | -$74.9M |
| Income Tax | — | — | — | — | — | $0 |
| Net Income | -$70.8M | -$80.8M | -$109.9M | -$97.3M | -$9.7M | -$74.9M |
| Diluted EPS | -$2.79 | -$2.29 | -$2.44 | -$1.59 | -$0.16 | -$1.18 |
Fulcrum Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$19.6M | -$20.3M | -$18.9M | -$26.2M |
| Diluted EPS | -$0.31 | -$0.32 | -$0.25 | -$0.34 |
Fulcrum Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $57.1M | $35.4M | $35.1M | $25.6M | $58.2M | $197.5M |
| Current Assets | $119.5M | $226.0M | $207.5M | $242.2M | $249.9M | $357.5M |
| Total Assets | $129.6M | $235.0M | $226.7M | $257.7M | $260.7M | $366.3M |
| Current Liabilities | $26.7M | $19.2M | $16.7M | $13.7M | $11.0M | $13.0M |
| Total Liabilities | $34.4M | $23.5M | $27.7M | $22.5M | $17.7M | $17.3M |
| Shareholders' Equity | $95.2M | $211.5M | $198.9M | $235.2M | $243.0M | $349.0M |
Fulcrum Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$53.7M | -$78.5M | -$97.0M | -$91.0M | -$2.2M | -$60.1M |
| Cash From Investing | -$57.1M | -$129.7M | $12.4M | -$36.7M | $32.2M | $30.7M |
| Cash From Financing | $71.1M | $186.5M | $84.3M | $118.1M | $2.7M | $168.7M |
| Free Cash Flow | -$55.0M | -$80.2M | -$99.0M | -$91.5M | -$2.5M | -$60.4M |
Figures from Fulcrum Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Fulcrum Therapeutics financials page for every line item.
Fulcrum Therapeutics Company Profile
| Ticker | FULC |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Cambridge, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001680581 |
Frequently Asked Questions
What was Fulcrum Therapeutics' revenue in fiscal 2025?
Fulcrum Therapeutics (FULC) reported revenue of $0 for fiscal 2025.
What is Fulcrum Therapeutics' annual revenue history?
Fulcrum Therapeutics' annual revenue by fiscal year: 2020: $8.8M; 2021: $19.2M; 2022: $6.3M; 2023: $2.8M; 2024: $80.0M; 2025: $0.
What was Fulcrum Therapeutics' net income in fiscal 2025?
Fulcrum Therapeutics reported net income of -$74.9M for fiscal 2025.
What was Fulcrum Therapeutics' earnings per share (EPS) in fiscal 2025?
Fulcrum Therapeutics' diluted EPS was -$1.18 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Fulcrum Therapeutics generate in fiscal 2025?
Fulcrum Therapeutics generated -$60.4M of free cash flow in fiscal 2025.
What was Fulcrum Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Fulcrum Therapeutics reported revenue of $0.
How many shares of Fulcrum Therapeutics are outstanding?
Fulcrum Therapeutics reported a weighted average of 76.3 million basic shares outstanding in 2026 Q2.
What is Fulcrum Therapeutics' market cap?
Based on its latest closing price, Fulcrum Therapeutics (FULC) has a market capitalization of about $280.7M.
When does Fulcrum Therapeutics' fiscal year end?
Fulcrum Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Fulcrum Therapeutics headquartered?
Fulcrum Therapeutics lists its business address in Cambridge, Massachusetts in its SEC filings.